Xin Lang Cai Jing·2026-01-06 04:15Group 1 - The core viewpoint of the news is that Junshi Biosciences experienced a significant increase in stock price and trading volume on January 5, with a rise of 6.62% and a transaction amount of 518 million yuan [1] - On January 5, Junshi Biosciences had a financing buy-in amount of 36.69 million yuan and a financing repayment of 52.40 million yuan, resulting in a net financing buy of -15.71 million yuan [1] - As of January 5, the total balance of margin trading for Junshi Biosciences was 1.341 billion yuan, with a financing balance of 1.327 billion yuan, accounting for 4.75% of the circulating market value, which is above the 60th percentile level over the past year [1] Group 2 - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [2] - For the period from January to September 2025, Junshi Biosciences achieved an operating income of 1.806 billion yuan, representing a year-on-year growth of 42.06%, while the net profit attributable to shareholders was -596 million yuan, an increase of 35.72% year-on-year [2] - As of September 30, 2025, the number of shareholders of Junshi Biosciences was 35,900, an increase of 15.17% compared to the previous period, with an average of 21,361 circulating shares per person, a decrease of 12.96% [2]